Αρχική World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC World News FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Από Ogkologos - 24 Ιουνίου, 2026 293 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... 5 Μαΐου, 2020 New targeted lung cancer screening programme on the horizon 29 Σεπτεμβρίου, 2022 FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... 22 Μαρτίου, 2024 Texas Baby Is Born With Almost No Skin On His Body,... 24 Απριλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... FDA Approves Relugolix for Advanced Prostate Cancer Making Important Decisions During Cancer: A Survivor’s Story